Controlled Trial of a New Anorectic Drug in the treatment of Obesity

Jt, Silverstone; Solomon, Thomas P. J.; Ross, Mary Frances; Kelly, Tanika N.

doi:10.1111/j.1742-1241.1967.tb06775.x

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1968

1999

Publication Types

Select...

Article2

Book1

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Mefenorex (RONDIMEN®)

Engel¹,

Kristen²,

Schaefer³

et al. 1986

Drug and Alcohol Dependence

View full text Add to dashboard Cite

Mefenorex, N-(3-chloropropyl)-alpha-methylphenethylamine, (RONDIMEN), is included in the list of centrally acting stimulants and/or hallucinogens or related compounds to be considered by a World Health Organization (WHO) Expert Committee in 1985 for possible scheduling under the Convention on Psychotropic Substances, 1971. The therapeutic efficacy of mefenorex as an adjunctive support in the treatment of obesity for limited periods of time, as well as its ability to be well tolerated, has been amply demonstrated. There have been no reports of actual abuse. There have been no reports of illicit trafficking, falsification of packages or materials, or clandestine laboratories manufacturing the compound. Data from preclinical and clinical studies do not suggest a potential for abuse similar to that of amphetamine or related compounds. Moreover, the lack of pulmonary hypertension with mefenorex has been demonstrated in both preclinical and clinical studies. There have been no reports of any public health or social problems associated with mefenorex use. The compound is a well-tolerated anorectic agent with little central stimulant activity.

show abstract